知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.015 秒)

    Antibodies Directed Against CD127
    6.
    发明申请
    Antibodies Directed Against CD127 审中-公开

    公开(公告)号：US20170129959A1

    公开(公告)日：2017-05-11

    申请号：US15317355

    申请日：2015-06-10

    申请人： OSE IMMUNOTHERAPEUTICS

    发明人： Nicolas POIRIER ,  Caroline MARY ,  Bernard VANHOVE

    IPC分类号： C07K16/28 ,  G01N33/68

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/5041 ,  G01N33/6854 ,  G01N2333/5418 ,  G01N2333/70546 ,  G01N2333/7155 ,  G01N2500/00

    摘要： The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and/or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.

    INHIBITORS OF PROTEINS SPECIFIC FOR THE SECRETOME OF A CHONDROCYTE FOR USE IN THE TREATMENT OF BREAST CANCER METASTASIS
    7.
    发明申请
    INHIBITORS OF PROTEINS SPECIFIC FOR THE SECRETOME OF A CHONDROCYTE FOR USE IN THE TREATMENT OF BREAST CANCER METASTASIS 审中-公开
    用于治疗乳腺癌的药物的秘密用蛋白质特异性蛋白质的抑制剂

    公开(公告)号：US20160069882A1

    公开(公告)日：2016-03-10

    申请号：US14786099

    申请日：2014-04-23

    申请人： ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG

    发明人： Prasad SHASTRI ,  Jon CHRISTENSEN ,  Xavier LUCAS ,  Stefan GÜNTHER

    IPC分类号： G01N33/574 ,  C07K7/08

    CPC分类号： G01N33/57415 ,  A61K38/00 ,  A61K38/10 ,  C07K7/08 ,  G01N33/574 ,  G01N33/68 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5418 ,  G01N2333/5421 ,  G01N2333/5428 ,  G01N2500/04

    摘要： The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases. The present invention further relates to a method for detecting breast cancer metastasis, comprising the step of detecting at least one protein that is specific for the secretome of a chondrocyte, and for methods for treating and/or preventing breast cancer metastasis in a patient in need thereof, comprising the step of administering an effective amount of at least one ligand for one protein that is specific for the secretome of a chondrocyte to said patient in need thereof.

    摘要翻译： 本发明涉及一种基于对软骨细胞分泌特异性蛋白（优选细胞因子和/或趋化因子）筛选的乳腺癌转移抑制剂的方法。 所鉴定的配体导致乳腺癌细胞的迁移和/或再分化的减少和/或乳腺癌转移的数量和/或尺寸的减少。 本发明还涉及一种用于检测乳腺癌转移的方法，包括检测至少一种对软骨细胞的分泌物具有特异性的蛋白质的步骤，以及用于在需要治疗的患者中治疗和/或预防乳腺癌转移的方法 其包括向有需要的所述患者施用有效量的至少一种配体，所述配体用于一种对软骨细胞分泌物特异的蛋白质。